Roche Toradol "Dear Doctor" letter cites inappropriate use uncovered by postmarketing study.

ROCHE TORADOL "DEAR DOCTOR" LETTER CITES INAPPROPRIATE USE seen in a 10,000 patient postmarketing study conducted by Roche's Syntex subsidiary. The letter, disclosed by Roche on Feb. 23, was sent to 60,000 physicians. The postmarketing study found physicians prescribing the nonsteroidal anti-inflammatory drug Toradol (ketorolac) to NSAID-sensitive patients; to patients with gastrointestinal bleeding; to elderly or renally impaired patients without proper dose modification; and for long-term use of Toradol tablets, the letter reports.